- Trials with a EudraCT protocol (102)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
102 result(s) found for: Immunofluorescence.
Displaying page 1 of 6.
EudraCT Number: 2016-002790-35 | Sponsor Protocol Number: C12-48 | Start Date*: 2019-02-07 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector | |||||||||||||
Medical condition: The trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000287-32 | Sponsor Protocol Number: D325AC00002 | Start Date*: 2020-12-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) | |||||||||||||
Medical condition: Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001859-35 | Sponsor Protocol Number: cro632 | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Abatacept in ANCA associated vasculitis: ABAVAS | |||||||||||||
Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004930-27 | Sponsor Protocol Number: MTOR-INHIBITION-SARCOIDOSIS | Start Date*: 2019-02-05 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis | ||
Medical condition: Sarcoidosis with cutaneous affections | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-005987-67 | Sponsor Protocol Number: AK802 | Start Date*: 2021-12-22 | |||||||||||
Sponsor Name:Akari Therapeutics Plc | |||||||||||||
Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem... | |||||||||||||
Medical condition: moderate to severe bullous pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000077-83 | Sponsor Protocol Number: SRP-9001-101 | Start Date*: 2022-11-10 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: Systemic gene delivery Phase I/IIa clinical trial for Duchenne muscular dystrophy using rAAVrh74.MHCK7.micro-dystrophin (microDys-IV-001) | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002391-14 | Sponsor Protocol Number: SAWV1003 | Start Date*: 2005-09-29 |
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | ||
Full Title: Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study | ||
Medical condition: ocular mucous membrane pemphigoid | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001780-27 | Sponsor Protocol Number: HTA-HG5-04 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Holostem Terapie Avanzate s.r.l. | |||||||||||||
Full Title: OPEN-LABEL, UNCONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF E... | |||||||||||||
Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient’s qu... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000756-42 | Sponsor Protocol Number: MEX0111 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dompé s.p.a. | |||||||||||||
Full Title: A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. | |||||||||||||
Medical condition: active bullous pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002333-40 | Sponsor Protocol Number: ARGX-113-1701 | Start Date*: 2018-01-31 | ||||||||||||||||
Sponsor Name:argenx BVBA | ||||||||||||||||||
Full Title: An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vul... | ||||||||||||||||||
Medical condition: Pemphigus (Vulgaris or Foliaceus) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003610-15 | Sponsor Protocol Number: RITUXVAS | Start Date*: 2005-12-15 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis. | ||
Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) CZ (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000793-20 | Sponsor Protocol Number: PNS2008-01 | Start Date*: 2008-05-05 | |||||||||||
Sponsor Name:Erasmus MC [...] | |||||||||||||
Full Title: Sirolimus (Rapamune®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes | |||||||||||||
Medical condition: Paraneoplastic Neurological Syndromes associated with anti-Hu antibodies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002836-18 | Sponsor Protocol Number: AK801 | Start Date*: 2018-05-07 | |||||||||||
Sponsor Name:Akari Therapeutics Plc. | |||||||||||||
Full Title: A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | |||||||||||||
Medical condition: Mild to Moderate Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004361-32 | Sponsor Protocol Number: KKS-166 | Start Date*: 2013-02-26 |
Sponsor Name:Philipps-Universität Marburg | ||
Full Title: Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study | ||
Medical condition: Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal p... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000605-72 | Sponsor Protocol Number: CB+MSCforEB | Start Date*: 2014-02-06 |
Sponsor Name:Universitair Medisch Centrum Utrecht | ||
Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa | ||
Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004884-19 | Sponsor Protocol Number: LENTICOL-F | Start Date*: 2016-05-24 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB) | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000171-36 | Sponsor Protocol Number: C20-54 | Start Date*: 2021-03-23 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA | |||||||||||||
Medical condition: Friedreich Ataxia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000261-36 | Sponsor Protocol Number: HTA-HG5-02 | Start Date*: 2021-09-07 | |||||||||||
Sponsor Name:HOLOSTEM TERAPIE AVANZATE S.R.L. | |||||||||||||
Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED ... | |||||||||||||
Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002439-14 | Sponsor Protocol Number: SHP640-301 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine... | |||||||||||||
Medical condition: Adenoviral Conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002330-38 | Sponsor Protocol Number: RituxiCAN-C4 | Start Date*: 2006-11-22 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy | |||||||||||||
Medical condition: Renal Transplant Rejection - chronic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
![](img/rss.png)
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
![](img/info.png)